A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

NCT01686217 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetics of ASP015K
Food Effect
Healthy Volunteers

Interventions

DRUG: ASP015K ER
DRUG: ASP015K IR

Sponsor

Astellas Pharma Global Development, Inc.